Refining liquid biopsy: generating more information from cell-free DNA
Liquid biopsy for profiling of cfDNA is transforming researchers’ efforts in early cancer detection, risk stratification, and disease monitoring. This poster illustrates how capturing complete genetic and modified cytosine (modC) information in one workflow, from a single low-volume DNA sample is morepowerful for the detection of early cancer than either alone. Top Take-Aways
biomodal launches solution to simultaneously sequence genetics and epigenetics in one workflow
biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sample, with […]
New beginnings: becoming biomodal
It all started with an epigenetic discovery Since Cambridge Epigenetix began in 2012, we’ve been innovating in the field of DNA sequencing and epigenetics. Back then, when Shankar Balasubramanian and Bobby Yerramilli‑Rao founded the company, the world was just starting to understand what epigenetic modifications meant to health and disease. We’d developed ways to measure […]
Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform
CAMBRIDGE, United Kingdom, Nov. 02, 2021 — Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point […]